R. Metz

发表

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

P. Fumoleau, C. Hill, P. Fargeot, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast Cancer

M. Namer, M. Marty, A. Monnier, 1990, American journal of clinical oncology.

CHAPTER 26 – SUPERIORITY OF AVCF (ADRIAMYCIN, VINCRISTINE, CYCLOPHOSPHAMIDE, AND 5-FLUOROURACIL) OVER CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL) AS ADJUVANT CHEMOTHERAPY FOR BREAST CANCER: A PHASE III TRIAL OF ASSOCIATION ONCOFRANCE

P. Fumoleau, G. Mathé, D. Belpomme, 1985 .

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

T. Delozier, M. Namer, L. Mauriac, 2005, Breast Cancer Research and Treatment.

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.

J. Bonneterre, M. Tubiana-Hulin, M. Spielmann, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized trial of prophylactic chemotherapy in T3-T4 breast cancer patients previously treated by radiotherapy.

M. Namer, G. Mathé, P. Chollet, 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Phase II clinical evaluation of doxifluridine.

S. Schraub, J. Armand, P. Fumoleau, 1986, Cancer treatment reports.

CHAPTER 35 – IMMUNOTHERAPY VERSUS CHEMOIMMUNOTHERAPY AS ADJUVANT TREATMENT OF MALIGNANT MELANOMA

G. Mathé, B. Mével, B. Serrou, 1985 .

Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer

J. Armand, J. Misset, G. Mathé, 2004, Investigational New Drugs.

Phase II trial with D‐Trp‐6‐LH‐RH in prostatic carcinoma: Comparison with other hormonal agents

A. Schally, P. Kerbrat, J. Misset, 1986, The Prostate.

An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma

A. Schally, P. Kerbrat, J. Misset, 1984, Medical oncology and tumor pharmacotherapy.

Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.

J. Bonneterre, P. Fargeot, P. Kerbrat, 1991, European journal of cancer.

Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).

J. Armand, P. Fumoleau, P. Kerbrat, 1993, European journal of cancer.

Follow-up results from a randomized trial for T3 and T4 breast cancer patients: previous BCG immunotherapy improves response to chemotherapy in the relapse patient.

G. Mathé, P. Chollet, N. Namer, 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.

P. Fumoleau, J. Misset, G. Mathé, 1986, Drugs under experimental and clinical research.